Reproductive Health Protection Program
Policy
It is the policy of the University of Nevada, Reno to minimize human reproductive health risks that are associated with University laboratories.
Responsible Authority
Vice President for Research and Innovation; Environmental Health & Safety Department (EH&S).
Scope
This policy applies to all University employees, students and volunteers who work in University owned or leased laboratories, or laboratory-support storerooms where biological, chemical, or physical reproductive health hazards are present.
Background
Many biological agents and hazardous chemicals that are used in laboratories are recognized as reproductive health hazards (see Appendix I for an example list of known or suspected reproductive hazards). Reproductive health hazards are of particular concern in cases of pregnancy, evaluation or treatment of infertility, or for preconception purposes. This policy describes the University reproductive health protection program applicable to university laboratories, both research and academic teaching laboratories. This policy covers biological, chemical, and physical reproductive hazards with specific guidance on ionizing radiation contained in the University’s Radiation Safety Manual.
Reference Regulations
29 CFR 1910.1200 (OSHA), Hazard Communication
29 CFR 1910.1450 (OSHA), Occupational Exposure to Hazardous Chemicals in Laboratories
Definitions
Reproductive Hazard
Biological or chemical agent, or physical stressor, that affects the reproductive capabilities of males or females, including chromosomal damage (mutations) and effects on fetuses (teratogens). Biological and chemical agents identified by Safety Data Sheets (SDSs) or other commonly accepted hazard information as producing reproductive effects are considered reproductive hazards.
Laboratory Supervisor
Person who has been assigned responsibility for a particular laboratory space or activity. For research laboratories the supervisor is the principal investigator (PI), and for teaching laboratories the supervisor is the instructor of record.
Responsibilities
Deans, Department Chairs, and Directors
Ensure that all principal investigators and laboratory supervisors are aware of the responsibilities and procedures contained in this policy and provide administrative support for implementation of this policy.
Deans are responsible fro approving reproductive health accommodation requests that are not within the scope of the Americans With Disabilities Act and making a final determination regarding accommodation requests when the laboratory supervisor has determined that accommodation is not reasonable.
Laboratory Supervisors and Laboratory Instructors
Identify recognized reproductive health hazards that are present in the laboratory or associated with laboratory work, and implement control methods to reduce personnel exposures to accepted safe levels.
Communicate information to laboratory personnel regarding reproductive hazards in the laboratory, to include the identity of reproductive hazards and the methods to be used to limit personnel exposures to accepted safe levels.
Implement appropriate engineered controls, safe work practices, and use of personal protective equipment so that personnel exposures to reproductive hazards are reduced to accepted safe levels, with the goal of eliminating reproductive hazards where feasible.
Upon receiving a Reproductive Health Declaration, ensure that provisions of this policy are carried out, to include review of reproductive health hazards and implementation of recommended exposure control methods and approved accommodations.
Laboratory instructors are responsible for completing a Reproductive Health Hazard Questionnaire for reproductive health declarations made by a student due to exposure to reproductive health hazards in an instructional laboratory class.
Laboratory Employees, Students, and Volunteers
As desired, declare pregnancy, preconception, or evaluation or treatment of infertility by submitting a Reproductive Health Declaration to Human Resources. If accommodation will be requested, complete the applicable section of the Reproductive Health Declaration form.
Once a reproductive health hazard declaration is made, the declaring individual is responsible for submitting a Reproductive Health Hazard Questionnaire to EH&S.
Human Resources
Provide consultation to the laboratory supervisor or instructor, and the responsible chair, director, or dean regarding work assignments and accommodations recommended by the declaring person’s personal physician or EH&S, or when requested by the declaring individual.
Environmental Health and Safety
Upon request, provide advice and service related to reproductive health risks, to include: 1) identification of reproductive health hazards, 2) exposure monitoring, 3) risk assessment, 4) methods to lower risks, and 5) information and training.
Procedure
Declaration of Pregnancy, Preconception, or Evaluation or Treatment of Infertility, and Request for Accommodation
- The individual who wants to declare their pregnancy, intent to conceive, or evaluation or treatment of infertility must submit a completed Reproductive Health Declaration Form (Appendix II) to the Human Resources Department (HR) at MS 0240.
- If the declared individual wants to request a reproductive health accommodation, he or she must make this request by completing the applicable portion of the Reproductive Health Declaration Form.
- HR will promptly forward a copy of the declaration form to the laboratory supervisor or instructor, and EH&S. If it appears to HR that the Americans With Disabilities Act may apply to the request, the declaration form shall also be forwarded to the Equal Opportunity/Title IX Office (EO/TIX Office) for consideration if the declarant is an employee, or to the Disability Resource Center (DRC) if the declarant is a student.
- If an accommodation was requested, HR will contact the laboratory supervisor or supervisor to discuss the request. If the requested accommodation is determined to be reasonable, the accommodation should be provided, with the approval of the responsible dean, unless the request falls under the scope of the Americans With Disabilities Act, which request will then be evaluated by the EO/TIX Office and the Accommodation Committee, or by the DRC as necessary. If the laboratory supervisor, instructor, Accommodation Committee, or DRC determines that the request is not reasonable, or not allowable due to grant funding restrictions, the accommodation request will be forwarded to the responsible dean for a final decision.
- Any accommodation for an employee must be a documented agreement between the affected person and their supervisor, with approval by the dean, and HR. The documentation should include an outline of temporary assignments and effective time periods and be signed by the declaring person, the laboratory supervisor or instructor; the dean; and HR representative.
Review of Reproductive Hazards
- If the declaring individual is an employee or volunteer he or she will complete the entire Reproductive Health Hazard Questionnaire (Appendix III) and submit it to EH&S. If the individual is declaring only as a student in an instructional laboratory class, he or she will complete only Section I of the questionnaire before submitting it to EH&S. If the individual is making a declaration as an employee/volunteer and as a student, he or she will submit multiple questionnaires, one for the research laboratory in which they work, and one for each academic instructional laboratory in which they are an enrolled student.
- When EH&S receives a questionnaire from a student, the questionnaire will be forwarded to the responsible laboratory instructor, who will complete Section II and return the questionnaire to EH&S.
- EH&S completes a reproductive health risk evaluation of the work area based on the completed questionnaire and a review of laboratory operations. EH&S provides a copy of the evaluation and any recommendations for reducing exposures to reproductive hazards to the declaring individual and the laboratory supervisor or instructor.
- The laboratory supervisor or instructor, EH&S representative, and the declaring individual will meet to review the questionnaire and evaluation.
Physician Review
- The declaring individual is encouraged to share the EH&S evaluation with his or her personal physician. The declaring individual is also encouraged to provide a copy of any work restrictions recommended by the personal physician to the laboratory supervisor. The physician’s recommended work restrictions must not include any personal medical information.
- The laboratory supervisor forwards any recommended work restrictions provided by the physician to HR and EH&S. If the laboratory supervisor has any questions about implementing the work restrictions he or she should consult with HR and EH&S as appropriate.
Related Documents
University Chemical Hygiene Plan
University Hazard Communication Program
University Radiation Safety Manual
References
- American College of Occupational and Environmental Medicine (1994) ACOEM Reproductive and Developmental Hazard Management Guidelines, Journal of Occupational and Environmental Medicine, January 1996, Volume 33, issue 1, pp. 83 – 90.
Appendix I: Examples of Known or Suspected Reproductive Hazards
The following list provides examples of biological, chemical, and physical agents that have been implicated as reproductive hazards. This list is intended as a guide, and is not inclusive. For more information on reproductive hazards review Safety Data Sheets and other sources of biological and chemical hazard information, or contact EH&S at (775) 327-5040.
Biological Agents
Viruses
- Arenaviruses (Hemorrhagic fever, Lasa fever)
- Cytomegalovirus
- Filoviruses (Marburg virus, Ebola virus)
- Hepatitis B virus
- Hepatitis C virus
- Herpes simplex virus
- Human immunodeficiency virus (HIV-1)
- Measles virus
- Mumps virus
- Parvovirus B19
- Rubella virus
- Varicella-zoster virus
Bacteria
- Borrelia burgdorferi (Lyme disease)
- Campylobacter sp.
- Chlamydia psitaci (psittacosis)
- Chlamydia trachomatis
- Clostridium perfringens
- Listeria monocytogenes
- Mycobacterium tuberculosis
- Mycobacterium leprae
- Neisseria gonorrhoeae
- Pasteurella multocida
- Borrelia sp. (relapsing fever)
- Salmonella sp.
- Treponema pallidum
Fungi
- Blastomyces dermatitidis (blastomycosis)
Parasites
- Plasmodium sp. (malaria)
- Toxoplasma gondii (toxoplasmosis)
Chemical Agents
| Chemical Name | CAS No | Source | Toxicological Designation |
|---|---|---|---|
| 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea | 13010-47-4 | Prop 65 | D |
| 1,2-Dibromo-3-Chloropropane (DBCP) | 96-12-8 | Prop 65 | M |
| 1,3,5-Triglycidyl-s-triazinetrione | 2451-62-9 | LANL, ACGIH | R |
| 1,3-Dioxolane | 646-06-0 | ACGIH | R |
| 1,4-Butanediol Dimethanesulfonate (Busulfan) | 55-98-1 | Prop 65 | D |
| 1-3-Butadiene | 106-99-0 | Prop 65 | D, F, M |
| 1-Bromopropane | 106-94-5 | Prop 65 | D, F, M |
| 1-Chloro-2-propanol | 127-00-4 | ACGIH | R |
| 1-Hexene | 592-41-6 | ACGIH | R |
| 1-Nitropropane | 108-03-2 | Reprotext A+ | N/A |
| 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) | 1746-01-6 | Prop 65 | D |
| 2,3-Xylidine | 87-59-2 | Reprotext A+ | N/A |
| 2,4-D Butyric acid | 94-82-6 | Prop 65 | M |
| 2,4-Xylidine | 95-68-1 | Reprotext A+ | N/A |
| 2,5-Xylidine | 95-78-3 | Reprotext A+ | N/A |
| 2,6-Xylidine | 87-62-7 | Reprotext A+ | N/A |
| 2-Bromopropane | 75-26-3 | Prop 65 | F, M |
| 2-Chloro-1-propanol | 78-89-7 | ACGIH | R |
| 2-Chloropropionic Acid | 598-78-7 | LANL, ACGIH | R |
| 2-Ethoxyethanol (EGEE) | 110-80-5 | LANL, ACGIH | R |
| 2-Ethoxyethyl Acetate (EGEEA) | 111-15-9 | LANL, ACGIH | R |
| 2-Ethylhexanoic Acid | 149-57-5 | ACGIH | N/A |
| 2-Methoxyethanol (EGME) | 109-86-4 | LANL, ACGIH | R |
| 2-Methoxyethyl Acetate (EGMEA) | 110-49-6 | LANL, ACGIH | R |
| 2-Nitropropane | 79-46-9 | Reprotext A+ | N/A |
| 3,4-Xylidine | 95-64-7 | Reprotext A+ | N/A |
| 3,5-Xylidine | 108-69-0 | Reprotext A+ | N/A |
| 4,6-Dinitro-o-cresol | 534-52-1 | Reprotext A+ | N/A |
| 4,6-Dinitro-o-cresol Diethylamine Salt | N/A | Reprotext A+ | N/A |
| 4,6-Dinitro-o-cresol Sodium Salt | 2312-76-7 | Reprotext A+ | N/A |
| Acetazolamide | 59-66-5 | Prop 65 | D |
| Acetohydroxamic acid | 546-88-3 | Prop 65 | D |
| Acrylic acid | 79-10-7 | LANL, ACGIH | R |
| Actinomycin D | 50-76-0 | Prop 65 | D |
| All-trans Retinoic Acid | 302-79-4 | Prop 65 | D |
| Alprazolam | 28981-97-7 | Prop 65 | D |
| Altretamine | 645-05-6 | Prop 65 | D, M |
| Amantadine Hydrochloride | 665-66-7 | Prop 65 | D |
| Amikacin Sulfate | 39831-55-5 | Prop 65 | D |
| Aminoglutethimide | 125-84-8 | Prop 65 | D |
| Aminoglycosides | N/A | Prop 65 | D |
| Aminomesitylene | 88-05-1 | Reprotext A+ | N/A |
| Aminopterin | 54-62-6 | Prop 65 | D, F |
| Amiodarone Hydrochloride | 19774-82-4 | Prop 65 | D, F, M |
| Amitraz | 33089-61-1 | Prop 65 | D |
| Amitrole | 61-82-5 | LANL, ACGIH | R |
| Ammonium Nitrate | 6484-52-2 | Reprotext A+ | N/A |
| Amoxapine | 14028-44-5 | Prop 65 | D |
| Amyl Nitrate | 1002-16-0 | Reprotext A+ | N/A |
| Anabolic Steroids | N/A | Prop 65 | F, M |
| Angiotensin Converting Enzyme (ACE) Inhibitors | N/A | Prop 65 | D |
| Aniline | 62-53-3 | Reprotext A+ | N/A |
| Anisindione | 117-37-3 | Prop 65 | D |
| Arsenic (inorganic oxides) | 7740-38-2 | Prop 65 | D |
| Aspirin | 50-78-2 | Prop 65 | D, F |
| Atenolol | 29122-68-7 | Prop 65 | D |
| Auranofin | 34031-32-8 | Prop 65 | D |
| Azathioprine | 446-86-6 | Prop 65 | D |
| Barbiturates | N/A | Prop 65 | D |
| B-Chloroprene | 126-99-8 | ACGIH | R |
| Beclomethasone Dipropionate | 5534-09-8 | Prop 65 | D |
| Benomyl | 17804-35-2 | ACGIH | D, M |
| Benzene | 71-43-2 | Prop 65 | D, M |
| Benzodiazepines | N/A | Prop 65 | D |
| Benzphetamine Hydrochloride | 5411-22-3 | Prop 65 | D |
| Bischloroethyl Nitrosourea (BCNU) (Carmustine) | 154-93-8 | Prop 65 | D |
| Bromacil Lithium Salt | 53404-19-6 | Prop 65 | D, M |
| Bromoadiolone | 28772-56-7 | Reprotext A+ | N/A |
| Bromoxynil | 1689-84-5 | Prop 65 | D |
| Bromoxynil Octanoate | 1689-99-2 | Prop 65 | D |
| Butabarbital Sodium | 143-81-7 | Prop 65 | D |
| Butyl benzyl Phthalate (BBP) | 85-68-7 | Prop 65 | D |
| Butyric Acid | 305-03-3 | Reprotext A+ | D |
| Cadmium | 7440-43-9 | Prop 65 | D, M |
| Carbamazepine | 298-46-4 | Prop 65 | D |
| Carbaryl (Sevin) | 63-25-2 | LANL, ACGIH | R |
| Carbon Disulfide | 75-15-0 | Reprotext A+ | D, F, M |
| Carbon Monoxide | 630-08-0 | ACGIH, A+ | D |
| Carboplatin | 41575-94-4 | Prop 65 | D |
| Chenodiol | 474-25-9 | Prop 65 | D |
| Chlorambucil | 305-03-3 | Prop 65 | D |
| Chlorcyclizine Hydrochloride | 1620-21-9 | Prop 65 | D |
| Chlordecone (Kepone) | 143-50-0 | Prop 65 | D |
| Chlordiazepoxide | 58-25-3 | Prop 65 | D |
| Chlordiazepoxide Hydrochloride | 438-41-5 | Prop 65 | D |
| Chloroform | 67-66-3 | LANL, ACGIH | R |
| Chlorophacinone | 3691-35-8 | Reprotext A+ | N/A |
| Chlorsulfuron | 64902-72-3 | Prop 65 | D, F, M |
| Cidofovir | 113852-37-2 | Prop 65 | D, F, M |
| Cladribine | 4291-63-8 | Prop 65 | D |
| Clarithromycin | 81103-11-9 | Prop 65 | D |
| Clobetasol Propionate | 25122-46-7 | Prop 65 | D, F |
| Clomiphene Citrate | 50-41-9 | Prop 65 | D |
| Clorazepate Dipotassium | 57109-90-7 | Prop 65 | D |
| Cobalt (II) Nitrate | 10141-05-6 | Reprotext A+ | N/A |
| Cocaine | 50-36-2 | Prop 65 | D, F |
| Codeine Phosphate | 52-28-8 | Prop 65 | D |
| Colchicine | 64-86-8 | Prop 65 | D, M |
| Conjugated Estrogens | N/A | Prop 65 | D |
| Copper Sulfate | 7758-98-7 | Reprotext A+ | N/A |
| Coumarin | 5836-29-3 | Reprotext A+ | N/A |
| Cupric Nitrate | 3251-23-8 | Reprotext A+ | N/A |
| Cyanazine | 21725-46-2 | Prop 65 | D |
| Cycloate | 1134-23-2 | Prop 65 | D |
| Cycloheximide | 66-81-9 | Prop 65 | D |
| Cyclophosphamide (anhydrous) | 50-18-0 | Prop 65 | D,F, M |
| Cyclophosphamide Hydrate | 6055-19-2 | Prop 65 | D,F, M |
| Cyhexatin | 13121-70-5 | Prop 65 | D |
| Cytarabine | 147-94-4 | Prop 65 | D |
| Dacarbazine | 4342-03-4 | Prop 65 | D |
| Danazol | 17230-88-5 | Prop 65 | D |
| Daunorubicin Hydrochloride | 23541-50-6 | Prop 65 | D |
| DDT | 50-29-3 | Prop 65 | D, F, M |
| Demeclocycline Hydrochloride | 64-73-3 | Prop 65 | D |
| Di(2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Prop 65 | D, M |
| Diazepam | 439-14-5 | Prop 65 | D |
| Diazoxide | 364-98-7 | Prop 65 | D |
| Dichlorophene | 97-23-4 | Prop 65 | D |
| Dichlorphenamide | 120-97-8 | Prop 65 | D |
| Diclofop Methyl | 51338-27-3 | Prop 65 | D |
| Dicumarol | 66-76-2 | Prop 65 | D |
| Diethylstilbestrol | 56-53-1 | Reprotext A+ | D |
| Diflunisal | 22494-42-4 | Prop 65 | D, F |
| Diglycidyl ether (DGE) | 2238-07-5 | LANL, ACGIH, B- | R |
| Dihydroergotamine Mesylate | 6190-39-2 | Prop 65 | D |
| Di-isodecyl Phthalate (DIDP) | 26761-40-0 | Prop 65 | D |
| Diltiazem Hydrochloride | 33286-22-5 | Prop 65 | D |
| Di-n-butyl Phthalate | 84-74-2 | Prop 65 | D, F, M |
| Di-n-hexyl Phthalate | 84-75-3 | Prop 65 | F, M |
| Dinitrotoluene | 25321-14-6 | ACGIH, A+ | F, M |
| Dinoseb | 88-85-7 | Prop 65 | D, M |
| Diphacinone | 82-66-6 | Reprotext A+ | N/A |
| Doxorubicin Hydrochloride | 25316-40-9 | Prop 65 | D, M |
| Epichlorohydrin | 106-89-8 | Prop 65 | M |
| Ethyl Acetate | 141-78-6 | Reprotext A+ | N/A |
| Ethyl tert-butyl ether (ETBE) | 637-92-3 | LANL, ACGIH | R |
| Ethylene Dibromide (EDB) | 106-93-4 | LANL | D, M |
| Ethylene Glycol Monethyl Ether Acetate | 111-15-9 | Prop 65 | D, M |
| Ethylene Glycol Monoethyl Ether | 110-80-5 | Prop 65 | D, M |
| Ethylene Glycol Monomethyl Ether | 109-86-4 | Prop 65 | D, M |
| Ethylene Glycol Monomethyl Ether Acetate | 110-49-6 | Prop 65 | D, M |
| Ethylene Oxide | 75-21-8 | ACGIH | F |
| Ethylenediamine | 107-15-3 | Reprotext A+ | N/A |
| Etodolac | 41340-25-4 | Prop 65 | D, F |
| Ferric Nitrate | 10421-48-4 | Reprotext A+ | N/A |
| Flunisolide | 3385-03-3 | Prop 65 | D, F |
| Fluorouracil | 51-21-8 | Reprotext A+ | D |
| Fluoxetine | 54910-89-3 | Reprotext A+ | N/A |
| Fluoxetine Hydrochloride | 59333-67-4 | Reprotext A+ | N/A |
| Flurbiprofen | 5104-49-4 | Prop 65 | D, F |
| Ganciclovir Sodium | 82410-32-0 | Prop 65 | D, M |
| Gemfibrozil | 25812-30-0 | Prop 65 | F, M |
| Goserelin Acetate | 65807-02-5 | Prop 65 | D, F, M |
| Haloperidol | 52-86-8 | Prop 65 | D, F |
| Halothane | 151-67-7 | LANL, ACGIH | D |
| Hexafluoroacetone | 684-16-2 | LANL, ACGIH | R |
| Hydramethylnon | 67485-29-4 | Prop 65 | D, M |
| Idarubicin Hydrochloride | 57852-57-0 | Prop 65 | D, M |
| Iodine | 7553-56-2 | Reprotext A+ | N/A |
| Iodine-131 | N/A | 10043-66-0 | D |
| Lead | 7439-92-1 | Reprotext 'A+, ACGIH | D, F, M |
| Lead Arsenate as Pb3(AsO4)2 | 3687-31-8 | ACGIH | R |
| Lead Chromate | 7758-97-6 | ACGIH | R |
| Lead Diamyldithiocarbamate | N/A | Reprotext A | N/A |
| Lead Dioxide | 1309-60-0 | Reprotext A+ | N/A |
| Lead Naphthenate | 61790-14-5 | Reprotext A | N/A |
| Lead Nitrate | 10099-74-8 | Reprotext A+ | N/A |
| Lead Oxide | 1317-36-8 | Reprotext A+ | N/A |
| Lead Tetroxide | 1314-41-6 | Reprotext A+ | N/A |
| Leuprorelin Acetate | 74381-53-6 | Prop 65 | D, F, M |
| Levodopa | 59-92-7 | Prop 65 | D |
| Levonorgestrel Implants | 797-63-7 | Prop 65 | F |
| Linuron | 330-55-2 | Prop 65 | D |
| Lithium Carbonate | 554-13-2 | Prop 65 | D |
| Lithium Citrate | 919-16-4 | Prop 65 | D |
| Lorazepam | 846-49-1 | Prop 65 | D |
| Lovastatin | 75330-75-5 | Prop 65 | D |
| Magnesium Nitrate | 10377-60-3 | Reprotext A+ | N/A |
| Magnesium Silicofluoride | 18972-56-0 | Reprotext A | N/A |
| Manganese | 7439-96-5 | LANL, ACGIH | R |
| m-Dinitrobenzene | 99-65-0 | Prop 65 | M |
| Mebendazole | 31431-39-7 | Prop 65 | D |
| Medroxyprogesterone Acetate | 71-58-9 | Prop 65 | D |
| Megestrol Acetate | 595-33-5 | Prop 65 | D |
| Melphalan | 148-82-3 | Prop 65 | D |
| Menotropins | 9002-68-0 | Prop 65 | D |
| Meprobamate | 57-53-4 | Prop 65 | D |
| Mercaptopurine | 6112-76-1 | Prop 65 | D |
| Mercuric Chloride | 7487-94-7 | Reprotext A+ | N/A |
| Mercuric Iodide | 7774-29-0 | Reprotext A+ | N/A |
| Mercury | 7439-97-6 | LANL, ACGIH | D, R |
| Methacycline Hydrochloride | 3963-95-9 | Prop 65 | D |
| Metham Sodium | 137-42-8 | Prop 65 | D |
| Methazole | 20354-26-1 | Prop 65 | D |
| Methimazole | 60-56-0 | Prop 65 | D |
| Methotrexate | 59-05-2 | Reprotext A+ | N/A |
| Methotrexate | 59-05-2 | Prop 65 | D |
| Methotrexate Sodium | 15475-56-6 | Prop 65 | D |
| Methoxyethyl Mercuric Acetate | 151-38-2 | Reprotext A+ | N/A |
| Methyl Bromide | 15475-56-6 | Prop 65 | D |
| Methyl Chloride | 74-87-3 | LANL, ACGIH | D, R |
| Methyl Isocyanate | 624-83-9 | Reprotext A+ | N/A |
| Methyl Mercury | N/A | Prop 65 | D |
| Methyl Tert-Butyl Ether (MTBE) | 1634-04-4 | LANL, ACGIH | R |
| Methylene Chloride | 75-09-2 | Reprotext A+ | N/A |
| Methylmercuric Dicyanamide | 502-39-6 | Reprotext A+ | N/A |
| Methyltestosterone | 58-18-4 | Prop 65 | D |
| Metiram | 9006-42-2 | Prop 65 | D |
| Midazolam Hydrochloride | 59467-96-8 | Prop 65 | D |
| Minocycline Hydrochloride (internal use) | 13614-98-7 | Prop 65 | D |
| Misoprostol | 59122-46-2 | Prop 65 | D |
| Mitoxantrone Hydrochloride | 70476-82-3 | Prop 65 | D |
| Molybdated Lead Chromate | 12213-61-5 | Reprotext A | N/A |
| Molybdated Lead Chromate | 12656-85-8 | Reprotext A | N/A |
| Myclobutanil | 88671-89-0 | Prop 65 | D, M |
| N,N-Dimethylacetamide | 127-19-5 | LANL, ACGIH | R |
| Nabam | 142-59-6 | Prop 65 | D |
| Nafarelin Acetate | 86220-42-0 | Prop 65 | D |
| Naphthalene | 91-20-3 | Reprotext A+ | N/A |
| n-Butyl Acrylate | 141-32-2 | LANL, ACGIH | N/A |
| n-Butyl Mercaptan | 109-79-5 | LANL, ACGIH | R |
| Nickel Carbonyl | 13463-39-3 | Reprotext A+ | D |
| Nicotine | 54-11-5 | Prop 65 | D |
| Nifedipine | 21829-25-4 | Prop 65 | D, F, M |
| Nimodipine | 66085-59-4 | Prop 65 | D |
| Nitrapyrin | 1929-82-4 | Prop 65 | D |
| Nitrobenzene | 98-95-3 | Reprotext A+ | N/A |
| Nitrofurantoin | 67-20-9 | Reprotext A+ | M |
| Nitrogen Mustard (Mechlorethamine) | 51-75-2 | Prop 65 | D |
| Nitrogen Mustard Hydrochloride | 55-86-7 | Prop 65 | D |
| Nitrous Oxide | 10024-97-2 | LANL, ACGIH | R |
| N-Methylpyrrolidone | 872-50-4 | Prop 65 | D |
| Norethisterone (Norethindrone) | 68-22-4 | Prop 65 | D |
| Norethisterone acetate (Norethindrone acetate) | 51-98-9 | Prop 65 | D |
| Norgestrel | 6533-00-2 | Prop 65 | D |
| o-Dinitrobenzene | 528-29-0 | Prop 65 | M |
| Oxadiazon | 19666-30-9 | Prop 65 | D |
| Oxazepam | 604-75-1 | Prop 65 | D |
| Oxydemeton Methyl | 301-12-2 | Prop 65 | F, M |
| Oxymetholone | 434-07-1 | Prop 65 | D |
| Oxytetracycline (internal use) | 79-57-2 | Prop 65 | D |
| Oxytetracycline hydrochloride (internal use) | 2058-46-0 | Prop 65 | D |
| Oxythioquinox (Chinomethionat) | 2439-01-2 | Prop 65 | D |
| Paclitaxel | 33069-62-4 | Prop 65 | D, F, M |
| Paramethadione | 115-67-3 | Prop 65 | D |
| PCB | 1336-36-3 | Reprotext A+ | N/A |
| PCB (Aroclor 1016) | 12674-11-2 | Reprotext A+ | N/A |
| PCB (Aroclor 1221) | 11104-28-2 | Reprotext A+ | N/A |
| PCB (Aroclor 1232) | 11141-16-5 | Reprotext A+ | N/A |
| PCB (Aroclor 1242) | 53469-21-9 | Reprotext A+ | N/A |
| PCB (Aroclor 1248) | 12672-29-6 | Reprotext A+ | N/A |
| PCB (Aroclor 1254) | 11097-69-1 | Reprotext A+ | N/A |
| PCB (Aroclor 1260) | 11096-82-5 | Reprotext A+ | N/A |
| PCB (Aroclor 1262) | 37324-23-5 | Reprotext A+ | N/A |
| PCB (Aroclor 1268) | 11100-14-4 | Reprotext A+ | N/A |
| PCB (Kanechlor 400) | 12737-87-0 | Reprotext A+ | N/A |
| p-Dinitrobenzene | 100-25-4 | Prop 65 | M |
| Penicillamine | 52-67-5 | Prop 65 | D |
| Pentobarbital sodium | 57-33-0 | Prop 65 | D |
| Pentostatin | 53910-25-1 | Prop 65 | D |
| Phenacemide | 63-98-9 | Prop 65 | D |
| Phenol | 108-95-2 | Reprotext A+ | N/A |
| Phenprocoumon | 435-97-2 | Prop 65 | D |
| Phenytoin Sodium | 630-93-3 | Reprotext A+ | N/A |
| Pimozide | 2062-78-4 | Prop 65 | D, F |
| Pipobroman | 54-91-1 | Prop 65 | D |
| Plicamycin | 18378-89-7 | Prop 65 | D |
| Potassium Dimethyldithiocarbamate | 128-03-0 | Prop 65 | D |
| Potassium Fluoride | 7789-23-3 | Reprotext A | N/A |
| Potassium Permanganate | 7722-64-7 | Reprotext A+ | N/A |
| Pravastatin Sodium | 81131-70-6 | Prop 65 | D |
| Prednisolone Sodium Phosphate | 125-02-0 | Prop 65 | D |
| Procarbazine Hydrochloride | 366-70-1 | Prop 65 | D |
| Propargite | 2312-35-8 | Prop 65 | D |
| Propylthiouracil | 51-52-5 | Reprotext A+ | D |
| Pyrimethamine | 58-14-0 | Prop 65 | D |
| Quazepam | 36735-22-5 | Prop 65 | D |
| Quizalofop-ethyl | 76578-14-8 | Prop 65 | M |
| Resmethrin | 10453-86-8 | Prop 65 | D |
| Ribavirin | 36791-04-5 | Prop 65 | D, M |
| Rifampin | 13292-46-1 | Prop 65 | D, F |
| Secobarbital Sodium | 309-43-3 | Prop 65 | D |
| Sermorelin Acetate | N/A | Prop 65 | D |
| Sodium Dimethyldithiocarbamate | 128-04-1 | Prop 65 | D |
| Sodium Fluoroacetate | 62-74-8 | Prop 65 | M |
| Sodium Iodide | 7681-82-5 | Reprotext A+ | N/A |
| Sodium Nitrite | 7632-00-0 | Reprotext A+ | N/A |
| Sodium Silicofluoride | 16893-85-9 | Reprotext A | N/A |
| Streptomycin Sulfate | 3810-74-0 | Prop 65 | D |
| Streptozocin | 18883-66-4 | Prop 65 | D, F, M |
| Strontium Nitrate | 10042-76-9 | Reprotext A+ | N/A |
| Sulindac | 38194-50-2 | Prop 65 | D, F |
| Tamoxifen Citrate | 54965-24-1 | Prop 65 | D |
| Temazepam | 846-50-4 | Prop 65 | D |
| Teniposide | 29767-20-2 | Prop 65 | D |
| Terbacil | 5902-51-2 | Prop 65 | D |
| tert -Amyl Methyl Ether (TAME) | 994-05-8 | ACGIH | R |
| Testosterone Cypionate | 58-20-8 | Prop 65 | D |
| Testosterone Enanthate | 315-37-7 | Prop 65 | D |
| Tetracycline (internal use) | 60-54-8 | Prop 65 | D |
| Tetracycline Hydrochloride (internal use) | 64-75-5 | Prop 65 | D |
| Tetranitromethane | 509-14-8 | Reprotext A+ | N/A |
| Thalidomide | 50-35-1 | Reprotext A+ | D |
| Thioguanine | 154-42-7 | Prop 65 | D |
| Thiophanate Methyl | 23564-05-8 | Prop 65 | F, M |
| Tobacco Smoke (primary) | N/A | Prop 65 | D, F, M |
| Tobramycin Sulfate | 49842-07-1 | Prop 65 | D |
| Toluene | 108-88-3 | Reprotext A+ | D |
| Triadimefon | 43121-43-3 | Prop 65 | D, F, M |
| Triazolam | 28911-01-5 | Prop 65 | D |
| Tributyltin Methacrylate | 2155-70-6 | Prop 65 | D |
| Trientine Hydrochloride | 38260-01-4 | Prop 65 | D |
| Triforine | 26644-46-2 | Prop 65 | D |
| Trilostane | 13647-35-3 | Prop 65 | D |
| Trimethadione | 127-48-0 | Prop 65 | D |
| Trimetrexate Glucuronate | 82952-64-5 | Prop 65 | D |
| Triphenyltin Hydroxide | 76-87-9 | Prop 65 | D |
| Uracil Mustard | 66-75-1 | Prop 65 | D, F, M |
| Uranium (VI) Dinitrate Oxide | 13520-83-7 | Reprotext A | N/A |
| Urethane (Ethyl Carbamate) | 51-79-6 | Prop 65 | D |
| Urofollitropin | 97048-13-0 | Prop 65 | D |
| Valproate (Valproic acid) | 99-66-1 | Prop 65 | D |
| Valproic Acid | 99-66-1 | Reprotext A+ | N/A |
| Vinblastine Sulfate | 143-67-9 | Prop 65 | D |
| Vinclozolin | 50471-44-8 | Prop 65 | D |
| Vincristine Sulfate | 2068-78-2 | Prop 65 | D |
| Vinyl Cyclohexene | 100-40-3 | LANL, ACGIH | R |
| Vinyl Cylohexene Dioxide | 106-87-6 | LANL, ACGIH | R |
| Warfarin | 81-81-2 | Reprotext A+ | D |
| Warfarin Sodium | 129-06-6 | Reprotext A+ | N/A |
| Xylidine | 1300-73-8 | Reprotext A+ | N/A |
| Zileuton | 111406-87-2 | Prop 65 | D, F |
Physical Agents
High sound levels
Heavy work, including heavy lifting
Prolonged standing
References
- Livingston, E. G. (1998) Infectious Agents and Noninfectious Biologic Products, in Reproductive Hazards of the Workplace, Frazier, L. M., Hage, M. L. (eds.), John Wiley and Sons (New York), Chapter 20, pp. 463-505.
- Lawrence Berkeley National Laboratory Chemical Hygiene and Safety Plan, revised 02/14, Chapter 45, Appendix D, LBNL Reproductive Toxins spreadsheet, http://www2.lbl.gov/ehs/pub3000/Ch35/Ch35_10.html#appd, accessed May 5, 2015.
- Greenberg, G. N., Cohen, B. A., Frazier, L. M., DeHart, R. L. (1998) Noise, Ultrasound, and Vibration, in Reproductive Hazards of the Workplace, Frazier, L. M., Hage, M. L. (eds.), John Wiley and Sons (New York), Chapter 17, pp. 401-414.
- Nesbitt, T. (1998) Ergonomic Exposures, in Reproductive Hazards of the Workplace, Frazier, L. M., Hage, M. L. (eds.), John Wiley and Sons (New York), Chapter 19, pp. 431-462.